Pharaon’s overall objective is to make a reality smart and active living for Europe’s ageing population by creating a set of integrated and highly customizable interoperable open platforms with advanced services, devices, and tools including IoT, artificial intelligence, robotics, cloud computing, smart wearables, big data, and intelligent analytics. Platform interoperability will be implemented within Pharaon ecosystems and platforms, as well as other standardised platforms within health and other domains (energy, transport and smart cities). Pharaon will consider relevant standards and will contribute to them with the help of the two standardisation bodies of the consortium. Data privacy, cybersecurity, interoperability and openness will be key design principles to pursue through the requirements generated by Pharaon experts. Pharaon will be built upon mature existing state-of-the-art open platforms and technologies/tools provided by the partners, which will be customised and will implement cloud technologies, AI techniques and traditional algorithms for big data intelligent analytics. A user-centric approach will be followed. Pharaon will evolve based on the user feedback and the results from a MAFEIP framework that will be implemented for impact assessment. Both inputs will be used to find innovative solutions through two “open calls”: (1) single solutions, and (2) solutions to be demonstrated in small-scale pilots. Pharaon’s integrated platforms will be validated in two stages: pre-validation and large-scale pilots (LSPs), in six different pilot sites: Murcia and Andalusia (Spain), Portugal, The Netherlands, Slovenia and Italy. A team of partners in each pilot will ensure its right development. A set of development tools will be created and made publicly available to simplify the customisation and integration. These tools and the results of dissemination will spread the generated knowledge to promote the development of new solutions similar to Pharaon.

Public procurers in ProEmpower aim to procure a disease self-management solution to help meet the imminent threat of a diabetes epidemic. ProEmpower will make person-centred care reality - giving the patient the steering wheel - for optimal health outcomes. Very significant synergies will be reaped by supporting all 10 action areas of diabetes management in an integrated ICT solution. Early detection, personal decision support, self management and peer support are to be delivered from a platform with full interoperable and secure access to the necessary devices and health records. ProEmpower will apply the internationally acclaimed Chronic Care Model to specify support needs for type 2 diabetes at all stages. Self-management and treatment will be supported by personalised guidelines and making the best use of clinical data. In this way a quality culture in healthcare will be fostered and learning healthcare systems made reality. Suppliers will be rigorously evaluated after each of the four procurement phases, comprising (I) an open market consultation supported by the European eHealth Competition, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 200 patients and 40 professionals. Fully rolled out in the four countries, enabled by procurers with the authority and capacity in their countries and regions, ProEmpower will serve 12 million diabetes patients. Reductions in diabetes-related death, amputation, blindness and renal failure promise cost relief of € 53 billion over 7 years in the four countries. Suppliers can expect a turnover of € 5 billion a year. Proven ability to cover the four different health systems promises ProEmpower suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.

The REVERT project will address the specific challenge of understanding at system level the pathophysiology of mCRC cancer in patients responding well or poorly to therapies, in order to design optimal strategy for mCRC on a case by case basis, with therapeutic interventions modulated depending on patient’s features. Accordingly, REVERT will build up an innovative artificial intelligence (AI)-based decision support system using the experience and the real-world data of several general Hospitals operating in the EU healthcare system ultimately aimed at developing an improved and innovative model of combinatorial therapy - based on a personalised medicine approach - that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable mCRC. This goal will be pursued through the building of the REVERT-DataBase (RDB) thanks to a large number of standardized biobank samples with related structured data, and clinical databases (including known clinical and biological features as well as new, potential prognostic/predictive biomarkers) from several major clinical European centres. The RDB, in turn, will be used to build a sophisticated computational framework based on AI to evaluate its impact on survival and quality of life in a prospective clinical trial through testing of new treatment sequences of the available and authorised molecular targeted drugs in patients with mCRC. In the end, the REVERT will also generate an EU- network among SMEs, Research Institutions, Clinical Centres and Biobanks focused on R&D in the field of AI-Health for the development of personalised medicine. The REVERT software system will ensure the integrity of data and privacy management in respect to national rules, the EU's GDPR (Reg. EU 2016/679) and the EU Charter of Fundamental Rights. The RDB and AI services will be open to all partners during and after project’s completion, available also to EU research Institutions for future studies.

The CHERRIES consortium, consisting of 12 renowned and EU-FP experienced universities, research organisations, SMEs, CSOs, healthcare organisations incl. a private hospital, business and innovation centres and regional authorities from seven European countries. The CHERRIES model will support healthcare research and innovation policy and pilot actions by interlinking RRI, demand-side policy and territorial innovation models incl. smart specialisation. This pilot innovation process will be implemented and tested in the territories of Murcia (ES), Örebro (SW) and the Republic of Cyprus (CY). Subsequently, three additional Mirror territories will be supported in adopting the CHERRIES model. The model applies RRI methods in the innovation process, not only contributing to more innovative territorial environments but also to more suitable single innovations that therefore have a higher chance of being widely adopted and establish them successfully on the market. With this innovative design processes, the project contributes to more open, transparent and democratic R&I systems in the engaged territories and beyond, creating societal, democratic, environmental, economic and scientific impacts as well as tackling transformation processes of the organisations involved.

European public entities are responsible of the provision of critical services like healthcare, education, justice, etc. In order to improve the delivery of their services to citizens over time they need to incorporate innovation. This innovation is often developed and produced by the private sector, for example in the form of technology. A standard model of incorporating innovation is through technology-push: private suppliers develop their innovative solutions, with limited contact and exchange with the public entities, and then try to commercialize them. This limited contact often leads to solutions that are not completely tailored or addressing a profitable need, as there is no real engagement in collaborative relations with the public administration. This sub-optimal interaction and knowledge of the customer needs and culture, leave start-ups and Small and Medium Enterprises (SMEs) with un-marketable products, discouraging them to fully engage with an important market (Public Procurement in Europe is estimated at €2 trillion, close to 20% of EU GDP ).